Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hikma Pharma Buys Stake in Hubei Haosun Pharma

publication date: Jul 11, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hikma Pharma, a Jordanian pharma with significant presence in the Middle East/North African region, paid $5 million to acquire a significant minority interest in Hubei Haosun Pharma. Haosun, which is privately held, develops and manufacturers difficult-to-make APIs with a specialization in oncology treatments. Hikma positioned the transaction as a means of gaining long-term access to high quality APIs. More details....     Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners